C0029944_NCI_CDISC-GLOSS | Knowledge4COVID-19

Property	Value
?:definition	Administration of a quantity of a medicinal product given per administration or cumulatively, which is above the maximum recommended dose according to the authorised product information. [After, EU Guideline on good pharmacovigilance practices (GVP)]
?:hasCUIAnnotation	<https://research.tib.eu/covid-19/entity/C0029944>
?:hasGeneratedBy	<https://research.tib.eu/covid-19/SourceName/NCI_CDISC-GLOSS>
?:type	<https://research.tib.eu/covid-19/vocab/AnnotationDefinition>

Metadata

Anon_0

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://purl.org/net/provenance/ns#DataItem>

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://www.w3.org/2004/03/trix/rdfg-1/Graph>

<http://xmlns.com/foaf/0.1/primaryTopic>

<https://research.tib.eu/covid-19/entity/C0029944_NCI_CDISC-GLOSS>

<http://xmlns.com/foaf/0.1/topic>

Anon_0

<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes>

<https://research.tib.eu/covid-19/data/entity/C0029944_NCI_CDISC-GLOSS>

<http://purl.org/net/provenance/ns#createdBy>

Anon_1 (more)

expand all